Chicken Lips
22 Jan 2016
Re: Edison Report Hi EdisonGood spot.Thanks for posting.
theprior
22 Jan 2016
Re: Edison Report Sound stuff, YB, I'd be happy with 20p for now with further growth later in the year !Regards, TP.
ybhere
22 Jan 2016
Edison Report Edison have produced a 15 page report on TRX. Very good, too big to copy/paste the whole article, just the following paraValuation: Sum-of-the-parts valuation of £346mOur DCF valuation is £346m (raised from £325m reflecting dollar appreciation) or 45.6p/sharebased on a WACC of 12.5%, subject to potential dilution from an estimated £15m funding requiredto deliver on our estimated growth trajectory. We value the wound care business at £188m, theorthopaedics division at £101m and £37m for the cardiac division, based on risk-adjusted cashflows for each division according to the stage of development; we add end-July 2015 net cash of£25m. According to our model, the current price gives a free option on Wound Care, the mostattractive and most commercially advanced division. There are a number of near-term catalystsahead, including the potential CE mark grant and launch of OrthoPure XM and US launch ofOrthoPure HM/HT via the HCTP pathway, which would lead us to increase the probability ofsuccess for these products.Financials: Wound care sales due to accelerate in 2016YB
waytogo333
21 Jan 2016
For what it's worth still think this is a great company, despite the current SP. Everything going in the right direction regarding sales and hopefully just a matter of time before the progress is reflected in the SP.
ybhere
20 Jan 2016
Re: RNSs Another great RNS today. Wait until the NHS and the rest of the worlds Health Care catches on.DermaPure® breaks through $1m sales markYork, 20 January 2016 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "The Group"
the regenerative medical devices company announces its dCELL® woundcare product DermaPure® has now surpassed the $1m sales mark, following its commercialisation in the US. DermaPure® was issued the Medicare 'Q' code for reimbursement in November 2014, which became effective as of January 1st 2015, and is now available to almost 65% of Medicare beneficiaries, spanning 31 states.The product is primarily aimed at the treatment of chronic wounds associated with diabetes. Approximately 10% of the American population are currently suffering from Type I or Type 2 diabetes, making the prevalence of hard to heal wounds, a common side effect of the disease, increase rapidly. In addition, DermaPure® is being used in a number of other varied clinical settings, treating conditions from pressure ulcers to frostbite. It is expected that Tissue Regenix, Woundcare Inc. will now develop this same dCELL® technology into products addressing other applications.
